NYSE:ADCTBiotechs
ADC Therapeutics (ADCT) Loss Narrowing To US$0.04 EPS Challenges Bearish Profitability Narrative
ADC Therapeutics (ADCT) closed out FY 2025 with Q4 revenue of US$23.1 million and a basic EPS loss of US$0.04, alongside net income excluding extra items of a US$6.4 million loss. The company has seen quarterly revenue move from US$16.9 million in Q4 2024 to US$23.1 million in Q4 2025, while basic EPS losses shifted from US$0.29 to US$0.04 over the same period. This sets the stage for investors to focus on how these headline figures translate into the quality and direction of margins.
See our...